SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Meta Expands AI Training With Employee Activity Tracking Tools 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
BURLINGAME, Calif., March 09, 2017 -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will host and provide a live webcast for its R&D Day, starting at 9:00 AM ET on March 14, 2017 in New York City.
The event will highlight the emerging role of the adenosine axis in immuno-oncology and its potential to address the limitations of existing agents. Additionally, Corvus will provide updates on its progress in clinical trials evaluating its lead CPI-444 program as well as the company’s pipeline.
Speakers at the event include:
- Jonathan D. Powell, MD, PhD (Johns Hopkins University)
- Lawrence Fong, MD (University of California, San Francisco)
- Richard Miller, MD (Corvus Co-Founder, President and CEO)
| R&D Day Webcast and Conference Call Details | |||||
| Event Title: | R&D Day Update: The Emergence of the Adenosine Pathway in Cancer Immunotherapy | ||||
| Date: | Tuesday, March 14, 2017 | ||||
| Time: | 9:00 - 12:00 p.m. ET | ||||
| Webcast: | The live webcast and slide presentation can be accessed at https://event.webcasts.com/starthere.jsp?ei=1137880 | ||||
An archive of the webcast will be available in the Investors section of the company's website for 30 days following the event.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Tecentriq® is a registered trademark of Genentech.
Corvus Contact: Jason Coloma SVP, Chief Business Officer Corvus Pharmaceuticals, Inc. +1-650-900-4511 [email protected] Media Contact: Julie Normart Pure Communications +1-415-946-1087 [email protected]
